The Paradox of Coronary Artery Calcification and the "Endpoint" Myth of Nutritional Interventions: Academic Reflections from Menaquinone-7, Niacin, and Berberine

The recently published VitaK-CAC randomized controlled trial demonstrates that supplementation with menaquinone-7 (MK-7) significantly attenuates the progression of coronary artery calcification (CAC) in patients with symptomatic coronary artery disease (CAD). While these findings appear promising, they raise important methodological and clinical-ethical questions regarding the longstanding assumption that increased vascular calcification generally correlates with atherosclerotic burden and cardiovascular risk. Contemporary understanding of vascular pathology suggests that calcification is not a homogeneous process; the transition from incipient to advanced calcification is a critical step in plaque healing and stabilization. Consequently, an important question emerges: does the inhibition of calcification progression truly arrest lesion deterioration, or might it inadvertently impede the consolidation of protective mineralization? Furthermore, does a reduction in calcification scores necessarily translate into meaningful clinical benefits for patients? History provides cautionary examples of interventions that favorably modified surrogate markers without improving hard clinical outcomes, as exemplified by niacin therapy, which improved lipid parameters but failed to reduce major cardiovascular events. Similar questions arise for emerging nutritional interventions, including berberine and other nutraceuticals, whose effects on biomarkers often precede definitive evidence of clinical efficacy. In this commentary, we examine the inherent limitations of relying on surrogate endpoints as the primary basis for clinical decision-making in nutritional medicine. Using the VitaK-CAC trial as a case study, we discuss the ethical and scientific imperative of demonstrating benefits on hard clinical outcomes, including cardiovascular events, mortality, quality of life, and functional status. We argue that rigorous evaluation of patient-centered outcomes is essential to ensuring that nutritional interventions serve patients' best interests and uphold the fundamental principles of evidence-based and ethical medical practice.